Immunotherapy as an adjunct to highly-active antiretroviral therapy.
Highly-active antiretroviral therapy (HAART) suppresses HIV viral replication and restores immune function in HIV-infected individuals, but HIV-1 can still persist in circulating, resting CD4+ T-cells. Recent studies demonstrate that adjunct immunotherapeutic strategies that enhance T-cell responses during HAART can, in certain cases, promote continued immune control of the AIDS virus after drugs are discontinued. However, development of immunotherapeutic strategies that target and eliminate the reservoir of HIV-1 infected, quiescent T-cells will likely be needed to achieve long-term control and eradication of the AIDS virus.
Murphey-Corb
M
M
University of Pittsburgh School of Medicine, Department of Molecular Genetics and Biochemistry, Biomedical Science Tower, Room E1252, Pittsburgh, PA 15261, USA. mcorb+@pitt.edu
Heydenburg-Fuller
D
D
D000818:Animals; D023241:Antiretroviral Therapy, Highly Active; D003131:Combined Modality Therapy; D015658:HIV Infections / Q000188:drug therapy / Q000628:therapy*; D015497:HIV-1; D006801:Humans; D007167:Immunotherapy; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014779:Virus Replication